Antithymocyte globulin (ATG) has been used in severe aplastic anemia (SAA) as a part of the conditioning regimen. Among the many kinds of ATG preparations, thymoglobulin had been found to be more effective in preventing GVHD and rejection of organ transplants. As the fludarabine-based conditioning regimens without total body irradiation have been reported to be promising for bone marrow transplantation (BMT) from alternative donors in SAA, thymoglobulin was added to fludarabine and cyclophosphamide conditioning to reduce GVHD and to allow good engraftment in unrelated BMT. Five patients underwent BMT with cyclophosphamide (50 mg/kg once daily i.v. on days À9, À8, À7 and À6), fludarabine (30 mg/m 2 once daily i.v. on days À5, À4, À3 and À2) and thymoglobulin (2.5 mg/kg once daily i.v. on days À3, À2 and À1) from HLA-matched unrelated donors. Complete donor type hematologic recovery was achieved in all patients. No serious complication occurred during BMT. Only one patient developed grade I acute GVHD resolved spontaneously. Except for one who had rupture of hepatic adenoma 78 days after BMT, all the other four patients are still alive with median 566 days. Fludarabine, cyclophosphamide plus thymoglobulin conditioning allows for the promising results of good engraftment, tolerable toxicity and minimal GVHD.
abine; cyclophosphamide; unrelated donor Bone marrow transplantation (BMT) from a matched family donor is a curative therapy for severe aplastic anemia (SAA). However, many patients have no appropriate family donor and they need another treatment such as immunosuppressive therapy and/or stem cell transplantation from an alternative donor. The known optimal conditioning for BMT from a matched sibling donor is the combination of cyclophosphamide and antithymocyte globulin (ATG), followed by GVHD prophylaxis with methotrexate and cyclosporine. 1, 2 Yet this regimen is insufficient for BMT from a matched unrelated donor. 3 Transplantation from a matched unrelated donor is associated with a high incidence of rejection, and so total body irradiation (TBI) has been added to the conditioning regimen to increase immunosuppression. [4] [5] [6] Recently, fludarabine-based conditioning regimens have been developed to avoid the short-and long-term side effects of irradiation in pediatric patients with promising results. 7 Although engraftment was achieved with this regimen, the problem of acute GVHD has not yet been solved.
ATG has been used in conditioning regimens for SAA. [1] [2] [3] [4] [5] 7, 8 It has also been used for BMT from unrelated donors in other disease to reduce graft failure and GVHD. [9] [10] [11] [12] [13] [14] [15] Among the many kinds of ATG, thymoglobulin (a rabbit derived antithymocyte polyclonal antibody) is known to be more potent than other preparations, and it has been found to be more effective for preventing GVHD and the rejection of organ transplants. [16] [17] [18] In this study, the more potent thymoglobulin was added to the fludarabine-based conditioning regimen for BMT from HLA matched unrelated donors in pediatric SAA, to reduce the GVHD with optimal engraftment without radiation toxicity.
Patients and methods

Patient and donor selection
From June 2002 to April 2003, five patients with SAA received BMT from HLA matched unrelated donors at Seoul National University Children's Hospital. The selection of donors was based on HLA serological typing performed for class I antigens and HLA molecular typing for the DRB1 loci. HLA-A, B, C, DRB1, and DQB1 loci were confirmed by a high-resolution molecular method (polymerase chain reaction single-strand conformation polymorphism) for all patients and donors.
Conditioning regimen
All patients received the same conditioning regimen after informed consent from their parents was obtained. The conditioning regimen was composed of cyclophosphamide (50 mg/kg once daily i.v. on days À9, À8, À7 and À6), fludarabine (30 mg/m 2 once daily i.v. on days À5, À4, À3 and À2) and thymoglobulin (SangStat, Lyon, France) (2.5 mg/kg once daily i.v. on days À3, À2 and À1). Patients received adequate hydration during the conditioning chemotherapy and they also received mesna to prevent hemorrhagic cystitis. Unmanipulated bone marrow was infused on day 0 of the conditioning regimen.
GVHD prophylaxis
Patients received cyclosporine (5 mg/kg/day i.v. by continuous infusion from day À2), methylprednisolone (0.5 mg/ kg/day i.v. from day 7 to day 13, 1.0 mg/kg/day from day 14 to day 27 followed by tapering over 8 weeks with oral prednisolone) and methotrexate (15 mg/m 2 i.v. on day 1, 10 mg/m 2 i.v. on days 3 and 6). Cyclosporine was tapered with an oral form and prescribed until 1 year after BMT. Patient number 5 received thymoglobulin (1.25 mg/kg once daily i.v. on days 7, 9 and 11) instead of corticosteroid owing to the pre-BMT morbidity of insulin dependent diabetes mellitus (DM).
Supportive care
Supportive care was administered according to the guidelines for stem cell transplantation of our center. 19 Patients received ciprofloxacin, fluconazole, isoniazid and acyclovir as a prophylaxis for infection. Intravenous immune globulin (0.5 g/kg/dose) was infused weekly until day 100, and then monthly until day 180. Daily sulfamethoxazole/ trimethoprim medication was discontinued 3 days before BMT and then restarted after WBC recovery. When fever exceeded 381C, broad-spectrum antibiotics were administered. Amphotericin B was given when fever persisted for more than 5 days despite an appropriate antibacterial treatment. CMV treatment with gancyclovir was started when CMV antigenemia was detected on routine weekly examination. Transfusions were given to maintain the hemoglobin level above 8 g/dl and the platelet count above 20 Â 10 9 /l. All blood products were irradiated with 20 Gy to avoid the risk of acute GVHD induction. G-CSF 300 mg/m 2 was administered from one day after the last methotrexate infusion and then discontinued when the absolute neutrophil count (ANC) increased to more than 1.0 Â 10 9 /l for 3 consecutive days. Patients received low-molecular weight heparin (nadroparine; fraxiparine, Sanofi-synthelabo, Paris, France) and/or lipo-PGE1 (eglandin; alprostadil, Welfide, Osaka, Japan) as a prophylaxis for veno-occlusive disease (VOD).
Assess engraftment and response
Myeloid engraftment was defined as the first of 3 consecutive days with an ANC of 0.5 Â 10 9 /l, and platelet recovery was defined as the day the platelet count was 50 Â 10 9 /l without platelet transfusions. Bone marrow was examined for morphology and cellularity at 1, 3 and 6 months after transplantation. Hematopoietic chimerism was evaluated by the analysis of a variable number of tandem repeats. The absolute lymphocyte count (ALC) on day 21 and lymphocyte subpopulations at 6 and 9 months after transplantation were analyzed to assess the immunologic recovery. Regimen-related toxicity was graded according to the NCI Common Toxicity Criteria for bone marrow transplant recipients (CTC 2.0). 20 
Results
Patient characteristics
The median time of transplant from diagnosis was 6 months (4-126 months). Two patients had hepatic adenoma owing to the long-term medication with oxymetholone. One patient had insulin dependent DM before transplantation. All the patients received serologically HLA-A, B matched and molecular HLA-DRB1 matched bone marrow. Three patients received HLA subtype mismatched bone marrow in one of 10 loci as confirmed with highresolution DNA typing. These patients were mismatched for HLA-A (0207 vs 0206), HLA-C (1402 vs 1405) or HLA-DQ1 (0301 vs 0302), respectively. The presenting Table 1 Characteristics and engraftment data of the five patients /kg), respectively. The median number of days required for ANC of more than 0.5 Â 10 9 /l and 1.0 Â 10 9 /l was 14 days (12-18 days) and 15 days (13-19 days) , respectively. The spontaneous platelet recovery to more than 20 Â 10 9 and 50 Â 10 9 /l required a median of 26 days (17-85 days) and 74 days (20-109 days), respectively. A median of 73.5 days (23-127 days) was required for platelet recovery to more than 100 Â 10 9 /l, except in one patient (dead before recovery). All patients become transfusion independent and achieved complete chimerism of donor hematopoiesis from day 28 and thereafter on bone marrow examination.
For patient number 1, who had a history of hepatic rupture before BMT, sudden death occurred 78 days after BMT owing to a recurrent hepatic rupture. All other patients are still alive at a median of 566 days (400-610 days) after BMT, and secondary graft failure has not yet occurred.
Complication and GVHD
During thymoglobulin infusion, all the patients had fever controlled with antipyretics. Complications resulting from BMT were fever (two patients), microscopic hematuria (five patients), abnormal liver function test (five patients) and diarrhea (three patients). But no grade 3 or 4 adverse events, VOD and treatment-related mortality occurred, and all the complications were mild and reversible. Pneumonia from some unknown organism occurred in two patients 2 months after BMT. One of them developed pulmonary fibrosis.
Only one patient (number 3), who received bone marrow from a perfectly matched donor for HLA-A, B, C, DR1 and DQ1, developed grade I acute GVHD (limited to localized skin) 74 days after BMT. This condition resolved spontaneously without any treatment. None of the patients has yet developed chronic GVHD.
Immunologic recovery and infection
The median ALC on day 21 was 0.43 Â /l). Although patient number 1 was dead before the recovery of T lymphocytes, normalization of the absolute CD3 þ , CD4 þ and CD8 þ cells counts was achieved 6 months after BMT in all available patents, except patient number 3 whose CD4 þ cells count recovered 9 months after BMT to the 5th percentile of age-matched reference value (Table 2) . 21 
Discussion
Optimal conditioning for BMT from a matched unrelated donor in SAA has not been defined yet. 2 Intensification of the conditioning regimens by the addition of TBI has improved the outcome. [4] [5] [6] Yet TBI has a deteriorative effect on growth, development, endocrine function, fertility and so on, and this is especially true for pediatric patients, 22 and the incidence of secondary malignancy is higher for the radiation containing conditioning regimen. 23 To avoid these problems, the non-TBI fludarabine based conditioning regimen could be optimal for pediatric patients. Chan et al 7 reported the promising results of conditioning regimens composed of fludarabine, cyclophosphamide and Atgam (a horse derived antithymocyte polyclonal antibody). In that study all five patients achieved full donor type engraftment, but four of them developed acute and chronic GVHD.
Many kinds of ATG preparations have been used to reduce graft rejection, graft failure and GVHD. Thymoglobulin (a rabbit derived antithymocyte polyclonal antibody) is known to be more effective for preventing organ rejection than Atgam or ATG-fresenius (a rabbit derived anti-Jurkat cell polyclonal antibody) in two controlled clinical trials. 16, 17 Thymoglobulin had been found to be more effective than the other anti-T cell antibody preparations in preventing GVHD. 13, 18 Although ATG is polyclonal in nature and different batches have a lot-to-lot variation, its mechanism of action is different according to the type of ATG. 24, 25 Thymoglobulin has been used as part of a conditioning regimen in aplastic anemia with promising results, 5 and it is the only ATG preparation proved to prevent GVHD and graft failure effectively in a randomized clinical study of unrelated BMT. 11 As thymoglobulin has been proven to be effective in an unrelated setting, we added thymoglobulin to fludarabine and cyclophosphamide, although Atgam was first used in the conditioning regimen of SAA. By this method, we achieved some promising results in this study. All the patients in our study achieved engraftment and only one patient developed grade I acute GVHD.
GVHD prophylaxis was composed of cyclosporine, corticosteroid and methotrexate in our study. This three drugs regimen was the modification of the one reported by Chao et al. 26 We extended the period of cyclosporine medication to 1 year instead of the 6 months of the original report. Patient number 5 had a history of insulin dependent DM and he could not receive corticosteroid as a GVHD prophylaxis. Therefore, we added three doses of thymoglobulin (1.25 mg/kg/day) after BMT instead of corticosteroid, as was proposed by Bacigalupo et al. 12 Acute and chronic GVHD did not developed in this patient. As steroid causes deteriorative effects such as cataract, hypertension and so on, we now use low-dose thymoglobulin instead of corticosteroid for GVHD prophylaxis of unrelated BMT in SAA.
Although the incidence and severity of GVHD was low, pulmonary complications such as pneumonia and pulmonary fibrosis did occur in this study. As the day 21 post BMT ALC of less than 0.35 Â 10 9 /l would seem to be associated with a high infection rate, 27 we analyzed this for all patients. But the median value of day 21 ALC in all the patients was more than 0.35 Â 10 9 /l, and there was no difference of mean ALC between the patients with pneumonia or without pneumonia. Deeg et al 4 reported the high incidence of pulmonary damage in unrelated BMT of SAA with a conditioning composed of cyclophosphamide, Atgam and minimum TBI. They proposed that the pulmonary damage might be caused by the presence of an unusual cytokine profile, like elevation of IL-10, present in a subgroup of aplastic anemia. The two patients with pulmonary problems in our study might have had abnormal cytokine profiles.
Patients number 1 and 5 have a long history of disease, but patients number 2, 3 and 4 received unrelated BMT after only minimal treatment with prednisolone and oxymetholone. Although it is not the current standard guideline for patients with SAA without matched family donor, 2,4 we decided to treat these patients with unrelated BMT because they had many matched donors available and delaying the BMT was not anticipated, and there were recent promising reports of unrelated BMT.
5-7 Although current standard treatment for patients without matched family donor is immunosuppressive therapy, this treatment could increase the number of the transfusions needed, which might induce allo-immunization for minor antigens and give deteriorative effects to the success of unrelated BMT. As BMT with matched family donor has become a standard therapy for SAA after the development of an excellent regimen, matched unrelated BMT could become a one of standard options for those patients without matched siblings if optimal conditioning regimens and GVHD prophylaxis are developed.
In conclusion, matched unrelated BMT with fludarabine, cyclophosphamide and thymoglobulin conditioning allowed for good engraftment without serious complications. The incidence and severity of acute GVHD was low but pulmonary complications were the problems that our regimen has to solve. A large prospective clinical study will prove the efficacy of our conditioning regimen.
